| Preview | Company (Stock code) | Event | Presenter |
|---|---|---|---|
 | INVION LIMITED (IVX) |
Invion successfully completes phase II study of INV02 (Nadolol) to aid smoking cessation Dr Mitchell Glass - Chief Medical Officer Tue, 06 Oct 2015 11:45 am (UK time) |
|
 | INVION LIMITED (IVX) |
Dr Mitchell Glass discusses Invion's phase II lupus clinical results Dr Mitchell Glass - Chief Medical Officer Tue, 18 Aug 2015 12:45 pm (UK time) |
|
| | INVION LIMITED (IVX) |
Invion update on INV102 (oral nadolol) Dr Mitchell Glass - Chief Medical Officer Tue, 19 May 2015 11:30 am (UK time) |
|
 | INVION LIMITED (IVX) |
Invion Interim Smoking Cessation Data Update Dr Mitchell Glass - Chief Medical Officer Mon, 19 Jan 2015 10:00 am (UK time) |
|
| | INVION LIMITED (IVX) |
Invion: Phase 2 INV102 trial Update Dr Mitchell Glass - Chief Medical Officer Tue, 23 Sep 2014 10:00 am (UK time) |
|
| | INVION LIMITED (IVX) |
Invion Ltd. Lupus Clinical Trial update Greg Collier - CEO & Managing Director Mon, 08 Sep 2014 03:00 pm (UK time) |
|
 | INVION LIMITED (IVX) |
Invion Limited Investor briefing ASX:IVX Dr Mitchell Glass - Chief Medical Officer Tue, 17 Jun 2014 11:00 pm (UK time) |
|
| | INVION LIMITED (IVX) |
Invion announces a significant agreement with 3M Drug Delivery Systems Greg Collier - CEO & Managing Director Fri, 21 Feb 2014 02:45 am (UK time) |
|